Please donate here to support this vital work.
Revealing News For a Better World

Psychedelic Medicine Media Articles
Excerpts of Key Psychedelic Medicine Media Articles in Major Media


Below are key excerpts of inspiring news articles on psychedelic medicine from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.


Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.


Psychedelic mushrooms put your brain in a “waking dream,” study finds
2014-07-03, Washington Post
http://www.washingtonpost.com/news/to-your-health/wp/2014/07/03/psychedelic-d...

Psychedelic mushrooms can do more than make you see the world in kaleidoscope. Research suggests they may have permanent, positive effects on the human brain. In fact, a mind-altering compound found in some 200 species of mushroom is already being explored as a potential treatment for depression and anxiety. People who consume these mushrooms, after “trips” that can be a bit scary and unpleasant, report feeling more optimistic, less self-centered, and even happier for months after the fact. But why do these trips change the way people see the world? According to a study published today in Human Brain Mapping, the mushroom compounds could be unlocking brain states usually only experienced when we dream, changes in activity that could help unlock permanent shifts in perspective. The study examined brain activity in those who’d received injections of psilocybin, which gives “shrooms” their psychedelic punch. After injections, the 15 participants were found to have increased brain function in areas associated with emotion and memory. The effect was strikingly similar to a brain in dream sleep, according to Dr. Robin Carhart-Harris, a post-doctoral researcher in neuropsychopharmacology at Imperial College London and co-author of the study. Administration of the drug just before or during sleep seemed to promote higher activity levels during Rapid Eye Movement sleep, when dreams occur. An intriguing finding, Carhart-Harris says, given that people tend to describe their experience on psychedelic drugs as being like “a waking dream.”

Note: For more on this, see concise summaries of deeply revealing mind altering drugs news articles from reliable major media sources.


How did Alexander Shulgin become known as the Godfather of Ecstasy?
2014-06-03, The Guardian (One of the UK's leading newspapers)
http://www.theguardian.com/science/shortcuts/2014/jun/03/alexander-shulgin-ma...

The explosion of dance music culture during the late '80s and early '90s conferred fame on some unlikely people, but few were quite as unlikely as Alexander Shulgin, who died on 2 June at his home in California at the age of 88. He was nearly 70 by the time he became known as the Godfather of Ecstasy, a title that made it sound like he had invented MDMA, which he hadn't: Shulgin had only introduced the drug to west coast psychotherapists in the late 70s. But, he had created more than 200 psychoactive compounds in his home laboratory, tested them all on himself and his wife and written about them in a 1991 book titled Phenethylamines I Have Known and Loved. The combination of the book, his association with ecstasy, and that drug's burgeoning popularity made him a hugely celebrated figure. Shulgin thought all drugs should be legalised, but he seemed about as far removed from the bug-eyed psychedelic proselyte of popular myth as it was possible to get. His writing was measured, calm and witty. He did not court the attention of the rave generation. If anything, he seemed faintly exasperated by the way MDMA was being used. "Go banging about with a psychedelic drug for a Saturday night turn-on, and you can get into a really bad place, psychologically," he had warned. Later he was to lament that MDMA had been "sidetracked into the Yahoo generation". None of the drugs Shulgin invented became as famous as the one he didn't. In the late '90s, there was talk that a compound called 2CB was "the new ecstasy" but it never attained the ubiquity of E. Nevertheless, Shulgin's legend was assured.

Note: To see Shulgin's fun and iconoclastic character, watch this fun four-minute video. Explore major media articles showing breakthroughs in therapy from an excellent compilation of news articles on mind altering drugs. And read the personal journey to healing of courageous CNN reporter Amber Lyon using these "medicines."


The Other Cannabis War?: The Battle Over Hemp
2014-06-03, Rolling Stone
http://www.rollingstone.com/politics/news/the-other-cannabis-war-20140603

Buried in February’s $956 billion farm bill is an amendment ... that legally distinguishes industrial hemp from marijuana, after decades of conflation [of the two]. It defines hemp as an agricultural crop rather than a drug — and effectively frees American farmers to grow it for the first time in almost 60 years. For 20 years, legislators, farmers, hippies, activists, agency heads and agronomists have worked to recast hemp as a game-changer, an American cash crop that could jump-start the country's next economic revival. Colorado, Vermont and Kentucky wasted no time launching their industrial hemp research and the pilot programs provided for in the farm bill. In an obscure notice dated April 16th, the USDA alerted state and county officials that farmers in states that [approved] hemp production (15 so far) could now include hemp acreage in their crop reports. The floodgates have opened. The current American hemp market is estimated at nearly half a billion dollars, with hemp’s oil, seed and fiber used in food, carbon-negative building materials, and automobile composites that are already inside millions of cars. Hemp cultivation is ... as old as the country itself. George Washington and Thomas Jefferson grew it, hemp was once legal tender, and several drafts of the Declaration of Independence were written on hemp paper. During WWII, American farmers were paid to grow it, cultivating more than 150 million pounds of industrial hemp to support the American war effort.

Note: Hemp is derived from the cannabis sativa plant, which also produces marijuana. For news on mind altering substances, see the deeply revealing reports from reliable major media sources available here.


The '60s Are Gone, But Psychedelic Research Trip Continues
2014-03-09, NPR
http://www.npr.org/2014/03/09/288285764/the-60s-are-gone-but-psychedelic-rese...

Psychedelic drug research is coming back. But the research still faces stigma, and funding is hard to get. Stanislav Grof was one of the leading researchers on the therapeutic applications of LSD in the 1950s and '60s. He studied the effect of hallucinogens on mental disorders, including addiction. Grof tells NPR's Arun Rath, "This was a tremendous deepening and acceleration of the psychotherapeutic process. Compared with the therapy in general, which mostly focuses on suppression of symptoms, here we had something that could actually get to the core of the problems." The Schedule 1 classification of LSD and other hallucinogenic substances in 1970 was a huge blow to research. But by the '90s, attitudes had begun to change. By the 2000s, a small but growing research community was picking up where Grof and others had left off. One area that showed promise was using hallucinogens to ease anxiety and depression in patients with cancer, like Erica Rex. "I was diagnosed with breast cancer, stage 2, in 2009," Rex says. "I went through the treatment, and then there are some drugs that have terrible side effects." She says she became obsessed with the possibility of her death, and it was crippling. Then Rex [was approved] for a study on the experimental drug psilocybin, an active compound in psychedelic mushrooms. In the end, she says, it helped her depression.

Note: Food justice champion Michael Pollan recently wrote a fascinating article prominently featured in the venerable magazine The New Yorker about the amazing power of psilocybin mushrooms to create profound healing in carefully controlled environments. It is subtitled "Research into psychedelics, shut down for decades, is now yielding exciting results." Are the healing potentials of mind altering drugs finally starting to receive honest mainstream attention?


LSD, Reconsidered for Therapy
2014-03-04, New York Times
http://www.nytimes.com/2014/03/04/health/lsd-reconsidered-for-therapy.html

On [March 4], The Journal of Nervous and Mental Disease is posting online results from the first controlled trial of LSD in more than 40 years. The study, conducted in the office of a Swiss psychiatrist near Bern, tested the effects of the drug as a complement to talk therapy for 12 people nearing the end of life. Most of the subjects had terminal cancer, and several died within a year after the trial — but not before having a mental adventure that appeared to have eased the existential gloom of their last days. “Their anxiety went down and stayed down,” said Dr. Peter Gasser, who conducted the therapy and followed up with his patients a year after the trial concluded. The new publication marks the latest in a series of baby steps by a loose coalition of researchers and fund-raisers who are working to bring hallucinogens back into the fold of mainstream psychiatry. Before research was effectively banned in 1966 in the United States, doctors tested LSD’s effect for a variety of conditions, including end-of-life anxiety. But in the past few years, psychiatrists in the United States and abroad — working with state regulators as well as ethics boards — have tested Ecstasy-assisted therapy for post-traumatic stress; and other trials with hallucinogens are in the works. “The effort is both political and scientific,” said Rick Doblin, executive director of the Multidisciplinary Association for Psychedelic Studies, a foundation that has financed many of the studies. “We want to break these substances out of the mold of the counterculture and bring them back to the lab.”

Note: For more on mind altering drugs, see the deeply revealing reports from reliable major media sources available here.


Why I changed my mind on weed
2013-08-09, CNN
http://edition.cnn.com/2013/08/08/health/gupta-changed-mind-marijuana/index.html

Over the last year, I [CNN Chief Medical Correspondent Dr. Sanjay Gupta] have been working on a new documentary called "Weed." The title "Weed" may sound cavalier, but the content is not. I traveled around the world to interview medical leaders, experts, growers and patients. I spoke candidly to them, asking tough questions. What I found was stunning. Long before I began this project, I had steadily reviewed the scientific literature on medical marijuana from the United States and thought it was fairly unimpressive. Reading these papers five years ago, it was hard to make a case for medicinal marijuana. I even wrote about this in a TIME magazine article, back in 2009, titled "Why I would Vote No on Pot." Well, I am here to apologize. I apologize because I didn't look hard enough, until now. I didn't look far enough. I didn't review papers from smaller labs in other countries doing some remarkable research, and I was too dismissive of the loud chorus of legitimate patients whose symptoms improved on cannabis. I mistakenly believed the Drug Enforcement Agency listed marijuana as a schedule 1 substance because of sound scientific proof. Surely, they must have quality reasoning as to why marijuana is in the category of the most dangerous drugs that have "no accepted medicinal use and a high potential for abuse." They didn't have the science to support that claim, and I now know that when it comes to marijuana neither of those things are true. It doesn't have a high potential for abuse, and there are very legitimate medical applications. In fact, sometimes marijuana is the only thing that works.

Note: This article was authored by CNN's Chief Medical Correspondent, Dr. Sanjay Gupta. For more on the proven benefits from many mind-altering drugs, see the deeply revealing reports from reliable major media sources available here.


'Absurd' drug laws 'hinder research' - Prof David Nutt
2013-04-06, BBC News
http://www.bbc.com/news/health-22042994

'Absurd' laws dealing with magic mushrooms, ecstasy and cannabis are hindering medical research, according to a former government drugs adviser. Prof David Nutt says he has funding to research the use of the chemical psilocybin - found in fungi known as "magic mushrooms" to treat depression. But he says "insane" regulations mean he cannot get hold of the drug. The Home Office said there was "no evidence" that regulations were a barrier to research. It is not the first time Prof Nutt has been at odds with government policy. He was sacked as an adviser over views that ecstasy and LSD were less harmful than alcohol. Earlier research at Imperial College London showed that injections of psilocybin could calm a region of the brain which is overactive in depression. The UK's Medical Research Council has given the lab a Ł550,000 grant to test the idea - in 30 patients who have not responded to at least two other therapies. They have also been given ethical approval. However, there are more stringent regulations for testing the drug as a treatment than in earlier experiments. As a potential medicine it must meet Good Manufacturing Practice requirements set out by the EU. "It hasn't started yet because the big problem is getting hold of the drug," said Prof Nutt. He said finding a company to provide a clinical-grade psilocybin had "yet proved impossible" as none was prepared to "go through the regulatory hoops". He told the BBC: "We have regulations which are 50 years old, have never been reviewed and they are holding us back, they're stopping us doing the science and I think it's a disgrace actually."

Note: Watch an informative three-minute BBC news clip of an interview with Prof. Nutt. Another good five-minute BBC interview is available here. For more on this, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources. See also the website of MAPS, and excellent organization supporting scientific study of the healing powers of these drugs.


U.S. hemp crop zero despite strong sales
2013-02-08, San Francisco Chronicle (SF's leading newspaper)
http://www.sfgate.com/business/article/U-S-hemp-crop-zero-despite-strong-sale...

$452 million: That's the value of retail products containing imported hemp that were sold in the United States in 2011. While a cousin of marijuana, the plant can't get you high. Instead, it can be used to make clothes, horse bedding, auto parts, soap and even concrete. But thanks to it being classified like all cannabis plants as a Schedule I substance - the same as heroin - the U.S. hemp crop is precisely zero. If you want to grow hemp and avoid a jail sentence, you need a permit from the Drug Enforcement Administration.

Note: Many have suspected that hemp was outlawed along with marijuana to block competition with lumber and other industries. To see a 1938 Popular Mechanics article touting hemp as the "new billion dollar crop," click here.


Experimental treatment for PTSD: Ecstasy
2012-12-03, CNN
http://www.cnn.com/2012/12/01/health/ecstasy-ptsd-1/

More than 7 million Americans suffer from PTSD, and by most estimates, only half of them -- at best -- are ever cured. A decade ago, the widely acknowledged need for better treatments opened the door to [South Carolina psychiatrist Dr. Michael] Mithoefer and his unconventional approach. By ... February 2005, the soft-spoken, ponytailed Mithoefer had managed to convince the Drug Enforcement Administration to green-light a study of Ecstasy as an adjunct to psychotherapy. He'd gotten the 3,4-methylenedioxy-methylamphetamine (MDMA) -- the chemical name for pure Ecstasy -- from Rick Doblin, the founder of a MAPS, the Multidisciplinary Association for Psychedelic Studies. The group's stated purpose is to develop "medical, legal and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana." It wants to turn mind-altering drugs like Ecstasy into prescription medicine. To win broader acceptance for MDMA -- and for cousins like LSD and psilocybin, the mind-altering compound in so-called magic mushrooms -- "the medical route was the only route. Everything else was blocked." That meant a formal plan for drug development: study protocols, institutional review boards and the rest. Mithoefer, a University of Virginia-trained clinician who specializes in trauma and had a long-running interest in MDMA, was the perfect partner.

Note: To watch a CNN video clip on this showing remarkable success in treating PTSD, click here. For deeply revealing reports from reliable major media sources on beneficial mind-altering drugs, click here.


A ‘Party Drug’ May Help the Brain Cope With Trauma
2012-11-20, New York Times
http://www.nytimes.com/2012/11/20/health/ecstasy-treatment-for-post-traumatic...

Hundreds of Iraq and Afghanistan veterans with post-traumatic stress have recently contacted a husband-and-wife team who work in suburban South Carolina to seek help. Many are desperate, pleading for treatment and willing to travel to get it. The soldiers have no interest in traditional talking cures or prescription drugs that have given them little relief. They are lining up to try an alternative: MDMA, better known as Ecstasy, a party drug that surfaced in the 1980s and ’90s that can induce pulses of euphoria and a radiating affection. Government regulators criminalized the drug in 1985, placing it on a list of prohibited substances that includes heroin and LSD. But in recent years, regulators have licensed a small number of labs to produce MDMA for research purposes. In a paper posted online ... by the Journal of Psychopharmacology, Michael and Ann Mithoefer, the husband-and-wife team offering the treatment — which combines psychotherapy with a dose of MDMA — write that they found 15 of 21 people who recovered from severe post-traumatic stress in the therapy in the early 2000s reported minor to virtually no symptoms today. The Mithoefers — he is a psychiatrist and she is a nurse — collaborated on the study with researchers at the Medical University of South Carolina and the nonprofit Multidisciplinary Association for Psychedelic Studies. The patients in this group included mostly rape victims, and experts familiar with the work cautioned that it was preliminary, based on small numbers, and its applicability to war trauma entirely unknown.

Note: For the paper on this remarkable study published published online in the Journal of Psychopharmacology, click here. For deeply revealing reports from reliable major media sources on beneficial mind-altering drugs, click here.


Law, policy thwart research on marijuana
2012-10-19, Boston Globe
http://bostonglobe.com/lifestyle/health-wellness/2012/10/18/research-into-mar...

Massachusetts voters in 2˝ weeks will consider becoming the 18th state to legalize the use of marijuana for medical purposes. Individual doctors and patient advocacy groups, including the AIDS Action Committee of Massachusetts and the state chapter of the Leukemia and Lymphoma Society, have endorsed the ballot question, saying marijuana can help patients and is available now. To study marijuana, researchers must be licensed by the US Drug Enforcement Administration and get access to marijuana grown at the University of Mississippi, which contracts with the National Institute on Drug Abuse to produce the only federally sanctioned supply. That process can prove onerous, if not impossible, acting as a deterrent for those who might want to study marijuana’s benefits, some researchers said. In 2000, the University of California created the Center for Medicinal Cannabis Research, with $9 million from the state. Dr. Igor Grant, the center’s director, ... and colleagues have completed the most comprehensive research to date of the effects of marijuana in patients, including studies that were randomized and double-blind, gold standards in research. Four studies found the drug to be useful in treating pain. Three were in patients with HIV who had pain resulting from damage to their nervous system. Another study found that marijuana reduced muscle stiffness in patients with multiple sclerosis.

Note: For deeply revealing reports from reliable major media sources on mind-altering drugs, click here.


Can LSD cure depression?
2012-09-25, The Telegraph (One of the UK's leading newspapers)
http://www.telegraph.co.uk/science/9565026/Can-LSD-cure-depression.html

Until recently, prescribing Ecstasy, mescaline or magic mushrooms has been a guaranteed way for a psychiatrist to lose his research funding, his job or even his liberty. But now, scientists are beginning to suspect that such illegal drugs may be the key to treating a range of intractable illnesses, from post-traumatic stress disorder to depression. These chemicals [include] the psychedelic drugs psilocybin, derived from magic mushrooms, and LSD, as well as Ecstasy. A series of studies performed in Britain and the US is beginning to tease out their potential benefits. “People become very emotionally tender on Ecstasy, which makes you more responsive to psychotherapy,” explains Dr Robin Carhart-Harris. [In] volunteers given the ... drug, the area of their brain involved in positive memories became more active, while another processing negative memories was damped down. “We think this would make it easier for patients to revisit a traumatic memory and overwrite or control it,” says Carhart-Harris. Earlier studies have made surprising discoveries about what psilocybin, a class-A drug in Britain, was doing in the brain. These in turn could lead to new treatments for depression and agonising cluster headaches. This may all sound radical, or even dangerous – yet half a century ago, research into the effects of psychedelic drugs was widespread and respectable. More than 1,000 papers were published looking at ways that psychiatrists could help patients with hallucinogenic chemicals.

Note: For deeply revealing reports from reliable major media sources on mind-altering drugs, click here.


Marijuana Fights Cancer and Helps Manage Side Effects, Researchers Find
2012-09-06, The Daily Beast/Newsweek
http://www.thedailybeast.com/articles/2012/09/06/marijuana-fights-cancer-and-...

Mounting evidence shows ‘cannabinoids’ in marijuana slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects. Peer-reviewed studies in several countries ... show that THC and other marijuana-derived compounds, known as “cannabinoids,” are effective not only for cancer-symptom management (nausea, pain, loss of appetite, fatigue), they also confer a direct antitumoral effect. A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings. THC treatment was associated with significantly reduced tumor cell proliferation in every test subject. Harvard University scientists reported that THC slows tumor growth in common lung cancer and “significantly reduces the ability of the cancer to spread.” What’s more ... THC selectively targets and destroys tumor cells while leaving healthy cells unscathed. Conventional chemotherapy drugs, by contrast, are highly toxic; they indiscriminately damage the brain and body. There is mounting evidence ... that cannabinoids “represent a new class of anticancer drugs that retard cancer growth, inhibit angiogenesis [the formation of new blood cells that feed a tumor] and the metastatic spreading of cancer cells.” Within the medical science community, the discovery that cannabinoids have anti-tumoral properties is increasingly recognized as a seminal advancement in cancer therapeutics.

Note: Yet treatment with cannabinoids continues to be largely illegal in the US. For an informative 15-minute documentary on the health benefits of juicing raw cannabis, click here. For deeply revealing reports from reliable major media sources on promising cancer-cure research, click here.


Scientists' agony over ecstasy
2012-07-18, The Guardian (One of the UK's leading newspapers)
http://www.guardian.co.uk/commentisfree/2012/jul/18/scientists-study-ecstasy-...

Research into ... Schedule I drugs like MDMA (ecstasy), LSD and magic mushrooms ... requires not only a high level of security, but also that the institutions involved buy a licence costing several thousand pounds not required for researching other drugs. Paradoxically, the other schedules include more harmful substances such as heroin. Funders often shy away from such research because of the red tape, associated higher costs, and the perception that it is possible to be stigmatised for supporting such work. Research into a Schedule I drug like MDMA has potential both to help our understanding of how drugs affect the brain, and provide those who take them with better harm-reduction information. It also helps us understand how we can make drugs work normally, advancing our treatment of brain disorders. Some Schedule I drugs have huge potential for serious conditions where treatment is currently inadequate, including addiction and depression. Frustratingly, almost no research has been carried out since current regulations came into force in 1971. And the situation is about to get worse; the government's new temporary drug control orders ... automatically puts new substances under Schedule I for the year that they are controlled. The likelihood of the drug then being downgraded is very remote, given that research will be practically impossible, especially within the year's timeframe.

Note: For deeply revealing reports from reliable major media sources on mind-altering drugs, click here.


A Judge’s Plea for Pot
2012-05-17, New York Times
http://www.nytimes.com/2012/05/17/opinion/a-judges-plea-for-medical-marijuana...

Three and a half years ago, on my 62nd birthday, doctors discovered a mass on my pancreas. It turned out to be Stage 3 pancreatic cancer. I was told I would be dead in four to six months. Today I am in that rare coterie of people who have survived this long with the disease. But I did not foresee that after having dedicated myself for 40 years to a life of the law, including more than two decades as a New York State judge, my quest for ameliorative and palliative care would lead me to marijuana. My survival has demanded an enormous price, including months of chemotherapy, radiation hell and brutal surgery. Inhaled marijuana is the only medicine that gives me some relief from nausea, stimulates my appetite, and makes it easier to fall asleep. The oral synthetic substitute, Marinol, prescribed by my doctors, was useless. Rather than watch the agony of my suffering, friends have chosen, at some personal risk, to provide the substance. I find a few puffs of marijuana before dinner gives me ammunition in the battle to eat. A few more puffs at bedtime permits desperately needed sleep. This is not a law-and-order issue; it is a medical and a human rights issue. Being treated at Memorial Sloan Kettering Cancer Center, I am receiving the absolute gold standard of medical care. But doctors cannot be expected to do what the law prohibits, even when they know it is in the best interests of their patients. When palliative care is understood as a fundamental human and medical right, marijuana for medical use should be beyond controversy.

Note: The author is Gustin L. Reichbach, who is a justice of the New York State Supreme Court in Brooklyn. For lots more from reliable sources on the benefits of many mind-altering drugs, click here.


Doctors consider using street drugs to ease suffering of dying patients
2012-04-24, Fox News
http://www.foxnews.com/health/2012/04/24/doctors-consider-using-street-drugs-...

Recent studies at Harvard, U.C.L.A. [and] John Hopkins have now made it plain that doctors should [soon] be free to offer illicit drugs to patients who are terminally ill, in order to ease their emotional suffering. At Harvard, Dr. John Halpern ... tested MDMA (the street drug Ecstasy) to determine if it would ease the anxieties in two patients with terminal cancer. At U.C.L.A. and Hopkins, Drs. Charles Grob and Roland Griffiths used psilocybin (the active ingredient in hallucinogenic mushrooms) to help cancer patients past their paralyzing, debilitating fears. The results are reportedly consistently good. In many cases, patients are able to cope with their physical pain and psychological turmoil better than before. Some, no doubt, feel the drugs opened doors of perception previously closed to them, allowing them to make peace with their lives and the impending end of their lives. Recent data also show that low doses of the street drug Special K (ketamine), when slowly infused via IV, can instantly [relieve] major depression ... in many patients. And opiates like oxycodone ... are also extremely useful for those patients who ... suffer with unwieldy anxiety that cannot be addressed ... in any other way.

Note: For more news articles from reliable sources on mind-altering drugs, click here.


How Psychedelic Drugs Can Help Patients Face Death
2012-04-22, New York Times
http://www.nytimes.com/2012/04/22/magazine/how-psychedelic-drugs-can-help-pat...

Charles Grob [is] a psychiatrist and researcher at Harbor-U.C.L.A. Medical Center who [has administered] psilocybin — an active component of magic mushrooms — to end-stage cancer patients to see if it could reduce their fear of death. When the research was completed in 2008 ... the results showed that administering psilocybin to terminally ill subjects could be done safely while reducing the subjects’ anxiety and depression about their impending deaths. Grob’s interest in the power of psychedelics to mitigate mortality’s sting is not just the obsession of one lone researcher. Dr. John Halpern, head of the Laboratory for Integrative Psychiatry at McLean Hospital in Belmont Mass., a psychiatric training hospital for Harvard Medical School, used MDMA — also known as ecstasy — in an effort to ease end-of-life anxieties in two patients with Stage 4 cancer. And there are two ongoing studies using psilocybin with terminal patients, one at New York University’s medical school, led by Stephen Ross, and another at Johns Hopkins Bayview Medical Center, where Roland Griffiths has administered psilocybin to 22 cancer patients and is aiming for a sample size of 44. “This research is in its very early stages,” Grob told me earlier this month, “but we’re getting consistently good results.” Grob and his colleagues are part of a resurgence of scientific interest in the healing power of psychedelics.

Note: For fascinating reports from major media sources on the beneficial uses of psychedelics, click here.


Can a hallucinogen from Africa cure addiction?
2012-04-13, BBC News
http://www.bbc.co.uk/news/magazine-17666589

Since the 1960s a disparate group of scientists and former drug addicts have been advocating a radical treatment for addiction - a hallucinogen called ibogaine, derived from an African plant, that in some cases seems to obliterate withdrawal symptoms from heroin, cocaine and alcohol. So why isn't it widely used? The drug, derived from the root of a central African plant called iboga, had been used for centuries by the Bwiti people of Gabon and Cameroon, as part of a tribal initiation ceremony. But it wasn't until 1962, when a young heroin addict called Howard Lotsof stumbled upon ibogaine, that its value as an addiction treatment was uncovered. Lotsof took it to get high but when the hallucinogenic effects wore off, he realised he no longer had the compulsion to take heroin. He became convinced that he had found the solution to addiction and dedicated much of his life to promoting ibogaine as a treatment. Ibogaine affects the brain in two distinct ways. The first is metabolic. It creates a protein that blocks receptors in the brain that trigger cravings, stopping the symptoms of withdrawal. With normal detox this process can take months. Its second effect is much less understood. It seems to inspire a dream-like state that is intensely introspective, allowing addicts to address issues in their life that they use alcohol or drugs to suppress.

Note: For more news articles from reliable sources on mind-altering drugs, click here.


Could A Club Drug Offer 'Almost Immediate' Relief From Depression?
2012-01-30, NPR blog
http://www.npr.org/blogs/health/2012/01/30/145992588/could-a-club-drug-offer-...

Traditional antidepressants like Prozac work on a group of chemical messengers in the brain called the serotonin system. Researchers once thought that a lack of serotonin was the cause of depression, and that these drugs worked simply by boosting serotonin levels. Recent research suggests a more complicated explanation. Serotonin drugs work by stimulating the birth of new neurons, which eventually form new connections in the brain. Ketamine, in contrast, activates a different chemical system in the brain – the glutamate system. Researcher Ron Duman at Yale thinks ketamine rapidly increases the communication among existing neurons by creating new connections. This is a quicker process than waiting for new neurons to form and accomplishes the same goal of enhancing brain circuit activity. Ketamine has been used for decades as an anesthetic. It also has become a wildly popular but illegal club drug known as "Special K." Mental health researchers got interested in ketamine because of reports that it could make depression vanish almost instantly. Carlos Zarate ... does ketamine research at the NIH. Zarate says patients typically say, "'I feel that something's lifted or feel that I've never been depressed in my life. I feel I can work. I feel I can contribute to society.' And it was a different experience from feeling high. This was feeling that something has been removed."

Note: For many inspiring potential treatment breakthroughs in health issues, click here.


Magic Mushrooms Expand the Mind By Dampening Brain Activity
2012-01-24, Time Magazine
http://healthland.time.com/2012/01/24/magic-mushrooms-expand-the-mind-by-damp...

More than half a century ago, author Aldous Huxley titled his book on his experience with hallucinogens The Doors of Perception. Huxley posited that ordinary consciousness represents only a fraction of what the mind can take in. In order to keep us focused on survival, Huxley claimed, the brain must act as a “reducing valve” on the flood of potentially overwhelming sights, sounds and sensations. What remains, Huxley wrote, is a “measly trickle of the kind of consciousness” necessary to “help us to stay alive.” A new study by British researchers supports this theory. It shows for the first time how psilocybin — the drug contained in magic mushrooms — affects the connectivity of the brain. Researchers found that the psychedelic chemical ... does not work by ramping up the brain’s activity as they’d expected. Instead, it reduces it. Under the influence of mushrooms, overall brain activity drops, particularly in certain regions that are densely connected to sensory areas of the brain. When functioning normally, these connective “hubs” appear to help constrain the way we see, hear and experience the world, grounding us in reality. Psilocybin cuts activity in these nodes and severs their connection to other brain areas, allowing the senses to run free. Huxley ... had predicted what turns out to be a key finding of modern neuroscience: many of the human brain’s highest achievements involve preventing actions instead of initiating them, and sifting out useless information rather than collecting and presenting it for conscious consideration.

Note: There are several excellent links in the full article which show promising results of using these plants to improve mental health and more.


Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

Kindly donate here to support this inspiring work.

Subscribe to our free email list of underreported news.

newsarticles.media is a PEERS empowerment website

"Dedicated to the greatest good of all who share our beautiful world"